Format

Send to

Choose Destination
J Biopharm Stat. 2003 Feb;13(1):87-101.

Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design.

Author information

1
Département de Biostatistique et Informatique Médicale, Hôpital Saint-Louis, AP-HP, Université Paris 7, Paris, France. szohar@chu-stlouis.fr

Abstract

We propose a new design for phase I (or phase II) dose-ranging clinical trials aiming at determining a dose of an experimental treatment to satisfy safety (respectively efficacy) requirements, at treating a sufficiently large number of patients to estimate the toxicity (respectively failure) probability of the dose level with a given reliability, and at stopping the trial early if it is likely that no dose is safe (respectively efficacious). A two-stage design was derived from the Continual Reassessment Method (CRM), with implementation of Bayesian criteria to generate stopping rules. A simulation study was conducted to compare the operating characteristics of the proposed two-stage design to those reached by the traditional CRM. Finally, two applications to real data sets are provided.

PMID:
12635905
DOI:
10.1081/BIP-120017728
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center